Article

Download article
Title: Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: Validation of luciferase as a quantitative tool
Author: Reimão, Juliana Q.; Trinconi, Cristiana T.; Yokoyama-yasunaka, Jenicer K.; Miguel, Danilo C.; Kalil, Sandra P.; Uliana, Silvia R.B.
Year: 2013
Is part of: Journal of Microbiological Methods, v. 93, p. 95 - 101
DOI: https://doi.org/10.1016/j.mimet.2013.02.007

Citation: Reimão, Juliana Q.; Trinconi, Cristiana T.; Yokoyama-yasunaka, Jenicer K.; Miguel, Danilo C.; Kalil, Sandra P.; Uliana, Silvia R.B.; Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: Validation of luciferase as a quantitative tool. Journal of Microbiological Methods, v.93, p. 95-101, 2013

Abstract: Given the lack of effective and safe alternatives to the drugs already in use, considerable efforts are being applied to the search of new therapeutic options to treat leishmaniasis. A necessary step in the discovery of antileishmanial drugs is the validation of drug candidates in mouse models. The standard methods to quantify the parasite burden in animal models, mainly culture-based, are time consuming and expensive. In recent years, in vivo imaging systems have been proposed as a tool to overcome these problems, allowing paraSite detection in living organisms. Here we compared different treatment efficacy evaluation approaches. Recombinant Leishmania (L) amazonensis lines expressing the luciferase gene (La-LUC) were obtained and characterized for biological properties as compared with the wild type (WT) parental line. Bioluminescence generated by La-LUC was shown to correlate with the number of promastigotes in vitro. La-LUC promastigotes and intracellular amastigotes were equally sensitive to amphotericin B (AmB) as the WT parasites. The clinical pattern of lesion development upon infection with the transgenic lines was similar to lesions observed after infection with the WT strain. The half maximal effective dose (ED50) of AmB was determined in La-LUC infected mice through quantification of bioluminescence in vivo and ex vivo, by limiting dilution and using clinical parameters. There was agreement in the ED50 determined by all methods. Quantification of bioluminescence in vivo and/or ex vivo was elected as the best tool for determining parasite burden to assess drug efficacy in infected mice. Furthermore, the detailed analysis of AmB effectiveness in this model generated useful data to be used in drug combination experiments. (C) 2013 Elsevier B.V. All rights reserved.



Funding: This work was supported by the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP 2011/20484-7) and the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico. The authors thank the FAPESP scholarship given to JQR (2011/21970-2) and to CMT (2011/18858-6). The authors also thank Thiago A. Souza and Susan I. Silva for the bioimaging technical assistance and Eliane M. Teixeira for scientific discussions.
Financed by: